NCT03951012View on ClinicalTrials.gov

Use Peripheral Blood Proteomics to Predict the Treatment Response and Toxicities in NSCLC Immunotherapy

TerminatedOBSERVATIONAL
Enrollment

29

Participants

Timeline

Start Date

April 15, 2019

Primary Completion Date

August 30, 2022

Study Completion Date

September 8, 2023

Conditions
Non Small Cell Lung Cancer
Interventions
PROCEDURE

Blood draw

Participants will be approached during their regular clinic visits and asked if an extra tube of blood may be collected prior to the treatment. If consent is not obtained before this visit, a participant will be asked later in the same day. The amount of blood collected will be 2 teaspoons (10mL).

Trial Locations (1)

52242

University of Iowa Hospitals and Clinics, Iowa City

Sponsors

Collaborators (1)

Biodesix, Inc.
All Listed Sponsors
collaborator

Biodesix, Inc.

INDUSTRY

lead

Muhammad Furqan

OTHER

NCT03951012 - Use Peripheral Blood Proteomics to Predict the Treatment Response and Toxicities in NSCLC Immunotherapy | Biotech Hunter | Biotech Hunter